| Execution period | 12 months |
|---|
BSE filing, BSE: 544759. Summary written from the filing by ALFA Finder's alert engine.
Goldline Pharmaceutical Ltd: key numbers
- Share price
- ₹29.98
- Market cap
- ₹28.78 Cr
- Revenue (annual)
- ₹31.20 Cr
- Net profit (annual)
- ₹4.12 Cr
- P/E (TTM)
- 7.0×Sector 47.2×
- Promoter holding
- 59.54%
- FII holding
- 0.31%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Goldline Pharmaceutical Ltd
All →Goldline Pharmaceutical Other Announcement
Goldline Pharmaceutical submitted a certificate confirming non-applicability of Regulation 74(5) for the quarter ended September 30, 2026, as all shares are in demat form.
Goldline Pharmaceutical Annual General Meeting
Goldline Pharmaceutical Ltd held its 22nd Annual General Meeting on August 29, 2026, where directors and key management presented financial performance and future business outlook.
Goldline Pharmaceutical Promoter Buying
Promoter Swapan Khandelwal increased his stake in Goldline Pharmaceutical Limited by 0.81% through an open market acquisition of 78,000 shares.
Goldline Pharmaceutical Other Announcement
Goldline Pharmaceutical Ltd announced the closure of its Register of Members and Share Transfer Books from August 23 to August 29, 2026, for its AGM.
Goldline Pharmaceutical Annual Report
Goldline Pharmaceutical Limited submitted its Annual Report for the financial year 2025-26, including the notice for the upcoming AGM on August 29, 2026.
Goldline Pharmaceutical Annual General Meeting
Goldline Pharmaceutical Limited has issued a notice for its 22nd Annual General Meeting, scheduled for August 29, 2026. The meeting will address financial statements, dividends, and director re-appointments.
Other management change announcements
All →Praveg Management Change
Praveg Limited's Company Secretary and Compliance Officer, Mukeshkumar Chaudhary, resigned effective November 3, 2026. Himalay Dudharejiya was appointed in his place from the same date.
DAM Capital Advisors Management Change
DAM Capital Advisors appointed Kishor Purshottam Thakkar as Non-Executive Independent Director for 60 months. Rajendra Prabhakar Chitale's tenure as Non-Executive Independent Director completed, with both changes effective 14 December 2026.
Vijaya Diagnostic Centre Management Change
Vijaya Diagnostic Centre appointed Rahul Jain as Company Secretary and Compliance Officer, designated KMP, effective November 03, 2026. The appointment follows the Nomination and Remuneration Committee's recommendation.
Endurance Technologies Management Change
Endurance Technologies' Compliance Officer Sunil Lalai resigned, effective 16 Nov 2026. Mandar Velankar is appointed Compliance Officer from the same date.
Transrail Lighting Management Change
Transrail Lighting appointed three senior management personnel and recorded two departures, effective 3 November 2026. Changes cover civil, poles and lighting, and supply chain roles.
Dipna Pharmachem Management Change
Dipna Pharmachem's board appointed two Additional Non-Executive Independent Directors and reconstituted the Audit, Nomination & Remuneration and Stakeholders Relationship Committees effective 3 November 2026. No capital, money, or business event is involved.